This report delves into the evolving landscape of Alzheimer's disease therapies, offering in-depth insights from interviews with key opinion leaders in the US and Europe. It examines the real-world deployment of anti-amyloid therapies like Leqembi and Kisunla, highlighting their promise and the logistical challenges faced in implementation. The report also explores the current and future treatment pathways, addressing unmet needs and the impact of pipeline therapies on the Alzheimer's treatment algorithm.
Gain insights on the advantages and limitations of existing treatments, the role of biomarkers, and the potential of emerging therapeutic strategies. This analysis is essential for pharmaceutical professionals seeking to navigate the complexities of Alzheimer's disease treatment and anticipate future developments in the field.
Key Questions Answered:
- 1. What treatments currently form the backbone of Alzheimer's disease (AD) therapy?
- 2. What are the advantages and disadvantages of current Alzheimer's treatments?
- 3. What are the current unmet needs and challenges in treating AD?
- 4. Which products are currently in the development pipeline for Alzheimer's treatment?
- 5. What impact are pipeline therapies expected to have on treatment pathways?
- 6. How is the AD treatment landscape expected to evolve over the next three to five years?
Key Brands:
- ACI 24
- ACI 35.030
- ACU 193 (sabirnetug)
- AL-002
- ALN APP (mivelsiran)
- ALZ 801 (valiltramiprosate)
- AR 1001 (mirodenafil)
- ATH-1017 (fosgonimeton)
- AV 1959D
- bepranemab
- BIIB 080
- blarcamesine
- Cobenfy (trospium chloride/xanomeline)
- contraloid
- elcubragistat
- Filora (simufilam)
|
- Kisunla (donanemab)
- Leqembi (lecanemab)
- LMTX (hydromethylthionine mesylate)
- LX 1001
- LY-3372993 (remternetug)
- NE3107 (bezisterim)
- Neu-P11 (piromelatine)
- pepinemab
- Posiphen (buntanetap)
- PRX012
- RG-6102 (trontinemab)
- RG6289
- Rybelsus (semaglutide oral)
- ABBV 916
- tertomotide
|
Methodology
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
